VEGF, VEGFR3, and PDGFRB protein expression is influenced by ras mutations in medullary thyroid carcinoma

Thyroid

Volumn 24, Issue 8, 2014, Pages 1251-1255

  Mancikova, Veronika ^a   Inglada Pérez, Lucía ^a,b   Curras Freixes, Maria ^a   De Cubas, Aguirre A ^a   Gómez, Álvaro ^a   Letón, Rocío ^a   Kersten, Iris ^a   Leandro García, Luis Javier ^a   Comino Méndez, Iñaki ^a   Apellaniz Ruiz, María ^a   Sánchez, Lara ^a   Cascón, Alberto ^a,b   Sastre Marcos, Julia ^c   García, Juan F ^d   Rodríguez Antona, Cristina ^a,b   Robledo, Mercedes ^a,b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL VIRGEN DE LA SALUD   (Spain)

^d MD ANDERSON CANCER CENTER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAS PROTEIN; SCATTER FACTOR RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; PROTEIN RET; RET PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; VEGFR3 PROTEIN, HUMAN;

ARTICLE; CODON; EXPLORATORY RESEARCH; GENE MUTATION; GERMLINE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE RAS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA; WILD TYPE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; THYROID TUMOR; TREATMENT OUTCOME;

DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; PROTO-ONCOGENE PROTEINS C-RET; RAS PROTEINS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; THYROID NEOPLASMS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84904706151     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0579     Document Type: Article

References (26)

1. Randolph GW, Maniar D 2000 Medullary carcinoma of the thyroid. Cancer Control 7:253-261. (Pubitemid 30387661)
2. Hofstra RM, et al. 1994 A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367: 375-376.
3. Wells SA Jr., et al. 2013 Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab 98:3149-3164.
4. Ciampi R, et al. 2013 Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 23:50-57.
5. Moura MM, et al. 2011 High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 96:E863-E868.
6. Leboulleux S, et al. 2004 Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 61:299-310. (Pubitemid 39287058)
7. Orlandi F, et al. 2001 Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer 8:135-147. (Pubitemid 32641355)
8. Almeida MQ, Hoff AO 2012 Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. Curr Opin Oncol 24:229-234.
9. Durante C, et al. 2013 Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. Endocrine 44:334-342.
10. Fox E, et al. 2013 Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res 19:4239-4248.
11. Kurzrock R, et al. 2011 Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660-2666.
12. Schlumberger MJ, et al. 2009 Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801.
13. Sherman SI, et al. 2013 Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: results from a phase III study. J Clin Oncol 31(suppl):363s, abstr 6000.
14. Rodriguez-Antona C, et al. 2013 Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma. Endocr Relat Cancer 20:611-619.
15. Linardou H, et al. 2008 Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and metaanalysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962-972.
16. Ceccherini I, et al. 1993 Exon structure and flanking intronic sequences of the human RET proto-oncogene. Biochem Biophys Res Commun 196:1288-1295. (Pubitemid 23347589)
17. Maderna E, et al. 2007 Nestin, PDGFRbeta, CXCL12 and VEGF in glioma patients: different profiles of (proangiogenic) molecule expression are related with tumor grade and may provide prognostic information. Cancer Biol Ther 6:1018-1024. (Pubitemid 351574951)
18. Rodriguez-Antona C, et al. 2010 Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 17:7-16.
19. Miliaras D, et al. 2004 KIT expression in fetal, normal adult, and neoplastic renal tissues. J Clin Pathol 57:463-466. (Pubitemid 38621789)
20. Lee JC, et al. 2010 Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. Mod Pathol 23:1379-1392.
21. Duncan TJ, et al. 2008 Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 14:3030-3035.
22. Hoff AO, Hoff PM 2007 Medullary thyroid carcinoma. Hematol Oncol Clin North Am 21:475-488; viii. (Pubitemid 46850792)
23. Treglia G, et al. 2012 Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine 42:535-545.
24. Maliszewska A, et al. 2013 Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions. Am J Pathol 182:350-362.
25. Boichard A, et al. 2012 Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab 97:E2031-E2035.
26. Wells SA Jr., et al. 2012 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134-141.